About: Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19
Creator	Min, Ji-Young Ko, Meehyun Shum, David Chang, So Choi, Inhee Windisch, Marc Young Byun, Soo Pham Hung D'alexandry D'orengiani, Anne-Laure
source	BioRxiv; MedRxiv
abstract	In 2015, the Middle East respiratory syndrome coronavirus (MERS-CoV) reached the Republic of Korea, resulting from nosocomial transmission, and was the largest epidemic outside of the Arabian Peninsula. To date, despite various strategies to identify CoV interventions, there are only limited therapeutic options available. To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including US Food and Drug Administration (FDA)-approved drugs and bioactive molecules, confirmed 221 hits by dose-response curve analysis in the primary assay, and selected 54 hits with a therapeutic index (TI) greater than 6. Time-of-addition studies with 12 FDA-approved drugs demonstrated that eight and four therapeutics act on the early- and late stages of the viral life cycle, respectively. Among the early acting drugs, three therapeutics with a TI greater than 100 were cardiotonic agents. Together, our results identify potential therapeutic options for treatment of MERS-CoV infections and could provide a basis for a wider range of coronaviruses, including the currently emerging coronavirus disease 2019 (COVID-19) outbreak.
has issue date	2020-03-02(xsd:dateTime)
bibo:doi	10.1101/2020.02.25.965582
has license	biorxiv
sha1sum (hex)	43cb651837d3ec906fd63ec8ca9e15a608cf9968
schema:url	https://doi.org/10.1101/2020.02.25.965582
resource representing a document's title	Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19
schema:publication	bioRxiv
resource representing a document's body	covid:43cb651837d3ec906fd63ec8ca9e15a608cf9968#body_text
is schema:about of	named entity 'INCLUDING' named entity 'RANGE' named entity 'ARABIAN PENINSULA' named entity '2015' named entity 'USED' named entity 'TO IDENTIFY' named entity 'NOSOCOMIAL TRANSMISSION' named entity 'HITS' named entity 'EARLY' named entity 'INFECTIONS' named entity 'POTENTIAL' named entity 'TREATMENT' named entity 'TIME' named entity 'coronavirus disease 2019' named entity 'approved drugs' named entity 'therapeutic index' named entity 'viral life cycle' named entity 'coronaviruses' named entity 'MERS-CoV' named entity 'COVID-19' named entity 'FDA' named entity 'South Korea' named entity 'approved drugs' named entity 'glycosides' named entity 'viral life cycle' named entity 'clathrin-mediated endocytosis' named entity 'dihydrochloride' named entity 'therapeutic index' named entity 'FDA' named entity 'nelfinavir mesylate' named entity 'HCS' named entity 'COVID-19' named entity 'viral life cycle' named entity 'MERS-CoV' named entity 'Standard deviation' named entity 'hydrochloride' named entity 'FDA' named entity 'digitoxin' named entity 'MERS-CoV' named entity 'FDA' named entity 'approved drugs' named entity 'approved drugs' named entity 'COVID-19 outbreak' named entity 'antiviral activity' named entity 'cardiotonic' named entity 'inhibitory concentration' named entity 'FDA' named entity 'calcium channels' named entity 'natural products' named entity 'Src kinase' named entity 'inhibitory concentration' named entity 'atovaquone' named entity 'hydrochloride' named entity 'spike (S) protein' named entity 'China' named entity 'MERS-CoV' named entity 'digoxin' named entity 'De Wilde' named entity 'antiviral' named entity 'Vero cells' named entity 'octocrylene' named entity 'clinical trials' named entity 'infection' named entity 'clinical development' named entity 'FDA' named entity 'viral life cycle' named entity 'cardiac glycosides' named entity 'cycloheximide' named entity 'hpi' named entity 'DMSO' named entity 'De Wilde' named entity 'chloroquine' named entity 'COVID-19' named entity 'DMSO' named entity 'antivirals' named entity 'digitoxin' named entity 'digoxin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software